A Complete Guide to Species and Strain Differences in Fibrosis Models: Mouse vs Rat, C57BL/6 vs BALB/c

1. Why Do Identical Treatments Produce Different Results?

"I administered bleomycin, but the lungs didn't fibrose," or "CCL4 didn't induce cirrhosis." Many researchers new to in vivo preclinical testing face these frustrating issues. Often, the root cause is not faulty techniques or expired reagents, but rather an incorrect choice of animal species or genetic strain.

Organ fibrosis is not simply a mechanical injury; it is a highly regulated cascade driven by immune responses and aberrant repair mechanisms. Consequently, using animals with fundamentally different baseline immune profiles or genetic backgrounds will drastically alter the phenotype.

This article explains why the C57BL/6 mouse is often considered the "king of fibrosis," and provides expert guidance on selecting the optimal species and strain for your specific research goals.

2. Species Differences: Mouse vs. Rat

The choice between a mouse and a rat goes far beyond differences in size and husbandry costs.

Mouse (Mus musculus)

Advantages: The unparalleled availability of genetic modification technologies (knockout/knockin/transgenic) makes mice the premier choice for functional analysis of specific molecules. Furthermore, the catalog of available antibodies, assay kits, and probes for mice is vastly superior to that for rats.
Characteristics: Distinct immune biases between different mouse strains allow researchers to tightly control the immunological environment (e.g., Th1 vs. Th2 dominance) of their models.
Primary Models: Bleomycin (BLM) pulmonary fibrosis, NASH/MASH diet-induced and STAM models, UUO (Unilateral Ureteral Obstruction), etc.

Rat (Rattus norvegicus)

Advantages: The larger tissue mass and blood volume of rats mean that significantly more material can be harvested from a single animal, making them ideal for comprehensive PK/PD (Pharmacokinetics/Pharmacodynamics) analyses and toxicology testing. Additionally, certain cardiovascular and metabolic pathways in rats more closely resemble human physiology.
Characteristics: Rats exhibit unique sensitivities in specific organ models, particularly in renal research.
Primary Models: Adenine-induced CKD model (Rats develop consistent, progressive renal failure and severe tubulointerstitial fibrosis mimicking human CKD much more reliably than mice), heart failure-associated cardiac fibrosis, and robust CCl4-induced liver fibrosis.

3. Mouse Strain Differences: Why C57BL/6 Dominates Fibrosis Research

When utilizing mice, selecting the correct inbred strain is critical. The most influential factor determining susceptibility to fibrosis is the innate balance between Th1 (cellular immunity) and Th2 (humoral immunity) responses.

C57BL/6 (B6) Mice: The First Choice

Immunological Profile: Th1-dominant (Pro-inflammatory). B6 mice readily produce pro-inflammatory cytokines like IFN-γ and mount aggressive inflammatory responses to tissue injury.
Fibrosis Susceptibility: Extremely High (Susceptible). Because the initial inflammatory insult is so intense, the subsequent repair process triggers massive collagen deposition and severe fibrosis.
Applications: The vast majority (estimated >80%) of pulmonary fibrosis (Bleomycin), MASH, and UUO models are performed on a B6 background to ensure robust and quantifiable disease progression.

BALB/c Mice: Strong Allergy, Weak Fibrosis?

Immunological Profile: Th2-dominant. BALB/c mice readily produce IL-4 and IL-13, making them the standard choice for allergy, asthma, and parasitic infection models.
Fibrosis Susceptibility: Relatively Low (Resistant / Less susceptible). For example, when challenged with bleomycin, BALB/c mice typically develop only mild, patchy fibrosis and demonstrate a much faster natural resolution of the disease compared to B6 mice.
The Paradox: While Th2 cytokines (like IL-13) are generally considered pro-fibrotic downstream, in models driven by acute chemical injury (like BLM), the severe early Th1/M1 macrophage-driven inflammatory storm is the primary prerequisite for initiating the fibrotic cascade. Thus, the Th1-skewed B6 mouse paradoxically develops worse fibrosis.

Other Notable Strains

C3H/HeJ: Carries a mutation in TLR4, rendering it resistant to LPS (endotoxin). Useful for teasing apart the contribution of innate immunity and gut-derived endotoxins in models like liver fibrosis.
DBA/2: Gaining attention in NASH research because it exhibits a lipid metabolism and transcriptomic profile that some studies suggest more closely mimics human hepatopathology compared to B6.

4. Examples in Validated Models

[Lung] Bleomycin-Induced Pulmonary Fibrosis

B6 Mice: Develop severe, widespread bridging fibrosis peaking around days 14-21. The undeniable standard for testing anti-fibrotic drugs.
BALB/c Mice: Fibrosis is localized, less severe, and resolves prematurely.
Conclusion: To reliably measure collagen reduction (drug efficacy), C57BL/6 is mandatory.

[Liver] Carbon Tetrachloride (CCl4)-Induced Liver Fibrosis

B6 vs. BALB/c: Literature suggests BALB/c mice may actually be more susceptible to the acute hepatotoxic necrosis of CCl4. However, repeated dosing in B6 mice reliably produces excellent bridging fibrosis, and B6 is heavily favored to match the background of knockout strains.
Rats (Wistar / Sprague-Dawley): Often preferred over mice for advanced hepatology studies. Their larger livers allow for reliable development of "micronodular cirrhosis" after prolonged CCl4 exposure, making them superior for studying portal hypertension and systemic hemodynamics.

[Kidney] Adenine-Induced Chronic Kidney Disease (CKD)

Rats (Wistar / SD): Feeding rats an adenine-enriched diet or administering it via oral gavage consistently leads to 2,8-DHA crystal deposition, severe tubulointerstitial fibrosis, and secondary hyperparathyroidism.
Mice (B6 etc.): Mice have a strong aversion to adenine. When it is mixed in their chow, they often exhibit severe cachexia and risk starvation before fibrosis fully develops. Creating this model in mice requires specialized diet formulations or continuous oral gavage, making the rat model significantly more practical and robust.

5. CRO Expert Advice: The Right Choice is the Foundation of Success

The animal model is the foundation of your entire study. Just because a published paper broadly uses the term "mice" does not mean you can use whatever surplus strain you have in your facility. Doing so risks wasting months of effort, valuable test compounds, and significant funding.

At our preclinical CRO, we guide clients through model selection based on three core criteria:

What is the target Mechanism of Action (MoA)?: Are you targeting early inflammation, late-stage collagen cross-linking, or metabolic dysfunction?
What are the sampling requirements?: If extensive blood sampling is needed for PK analysis alongside tissue harvesting, rats are the pragmatic choice.
Natural History of the Model: Will the chosen strain naturally resolve the fibrosis before your drug has a chance to show an effect?

To generate compelling, highly translational data using quantitative methods like Sirius Red Morphometry and Hydroxyproline Assays, you must start with a reliable, highly sensitive, and reproducible animal model.

If you need guidance on model selection or are looking to outsource your efficacy studies, our team of fibrosis experts is here to support your drug discovery program from start to finish.

👉 Contact Us for Preclinical Fibrosis Models

References

Walkin L, et al. The role of mouse strain differences in the susceptibility to fibrosis: a review. Fibrogenesis Tissue Repair. 2013;6(1):18.
Peng R, et al. Bleomycin-induced pulmonary fibrosis in mice: a nuanced look at strain differences. Am J Physiol Lung Cell Mol Physiol. 2013;305(9):L585-L596.
Tsuchida T, et al. Distinctive features of adenine-induced tubulointerstitial nephritis in mice and rats. Nephrology. 2020.